On October 13, 2026 Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, reported that an abstract submitted by its partner, VelaVigo, has been accepted for an oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Asia Congress 2026 taking place in Singapore from December 4–6, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VelaVigo will present preliminary safety, tolerability, and efficacy results from its ongoing Phase 1 study evaluating VBC103 (known as AVZO-103 outside of Mainland China, Hong Kong, Macau and Taiwan (collectively, "Greater China"), a bispecific Nectin-4/TROP2 antibody-drug conjugate ("ADC") that VelaVigo is developing in Greater China.

Details of the oral presentation are as follows:
Abstract: 2370
Title: First-in-human study of VBC103, a bispecific antibody-drug conjugate (ADC) targeting Nectin-4 and TROP2 as monotherapy in participants with advanced solid tumors
Speaker: Prof. Jian Zhang, Fudan University Shanghai Cancer Center
Session: Developmental therapeutics and precision medicine
Presentation Date and Time: Friday, December 4, 2026, 10:45–10:55 a.m. SGT
Location: Hall 402, Suntec Singapore Convention & Exhibition Centre

Avenzo is developing AVZO-103 outside of Greater China and is currently conducting a Phase 1/2 clinical study in patients with metastatic urothelial cancer or other solid tumors.

About AVZO-103

AVZO-103 (known as VBC103 in Greater China) is a potentially differentiated bispecific ADC designed to simultaneously target Nectin-4 and TROP2, two tumor antigens that are highly co-expressed across multiple solid tumors, including urothelial cancer. AVZO-103 is designed to address tumor heterogeneity and deliver a potent topoisomerase I inhibitor payload that may help overcome resistance to prior therapies. It is potentially a first-in-class molecule, being the first Nectin-4/TROP2 bispecific ADC to enter clinical development in the U.S. Avenzo is evaluating AVZO-103 in the BEACON-1 Phase 1/2 clinical study in patients with advanced solid tumors. The U.S. Food and Drug Administration has granted Fast Track designation to AVZO-103 for the treatment of adult patients with locally advanced or metastatic urothelial cancer previously treated with enfortumab vedotin. Avenzo holds exclusive global rights, excluding Greater China, from VelaVigo to develop, manufacture and commercialize AVZO-103.

(Press release, Avenzo Therapeutics, OCT 13, 2026, View Source [SID1234673366])